SPL Medical B.V. announced today the headline results of the pivotal phase III study PROSTAPROGRESS (EudraCT 2018-004310-18), aiming to assess the diagnostic accuracy of Ferumoxtran enhanced Magnetic Resonance Imaging (MRI) for lymph node detection in prostate cancer patients....
SPL Medical announced today the publication and online availability of the full paper in European Radiology about the use of Ferrotran® for lymph node detection in pancreatic and other adenocarcinoma....
The business agreement, signed by SPL Medical and Sanochemia Pharmazeutika, is a comprehensive contract. The agreement grants Sanochemia worldwide exclusivity regarding the supply and distribution of Ferrotran® (an iron oxide-based nanoparticle) for use in Magnetic Resonance Imaging (MRI) except for Germany, Austria and Switzerland. These ...
The business agreement, signed today by SPL Medical and NanoEcho, is a comprehensive contract. The agreement grants NanoEcho exclusivity regarding the supply of ferumoxtran (iron oxide-based nanoparticles) for use in magnetomotive ultrasound. ...
Die bender gruppe gibt bekannt, dass sie mit der Entwicklung einer KI-Software zur Detektion von Mikrometastasen mittels MRT-Scans von Lymphknoten bei Prostatakrebserkrankungen begonnen hat. Die bender gruppe ist 100%-ige Gesellschafterin der medigration GmbH aus Erlangen, einem etablierten RIS/PACS-Entwicklungsunternehmen sowie Mehrheitsgesellschafterin der SPL Medical BV, mit...
SPL medical has its proprietary iron-based nano-particle Ferrotran® (Ferumoxtran) product and platform in clinical Phase III. The pivotal trial named PROSTAPROGRESS has now reached the next major milestone by inclusion of over 75% of the patients into this trial....
SPL medical and NanoEcho have signed a Letter of Intent and initiated a cooperation on regulatory partnership and supply for SPL medical proprietary iron-based nanoparticle Ferrotran® (Ferumoxtran) product and platform....
SPL Medical is pointing out a powerful publication in Investigative Radiology elaborating a new reading algorithm for nanoparticle-MRI with Ferrotran® (Ferumoxtran) for the detection of even very small lymph nodes in head & neck cancer patients....
SPL Medical is pointing out a powerful publication in European Urology Focus highlighting the useability of Ferrotran® (Ferumoxtran) for MR-Angiography (MRA) even in renally impaired patients thus providing access to another market of approx. 1.5 bln USD with high growth rates....
SPL Medical announced today that it has entered into an agreement for the distribution of its novel contrast agent Ferrotran® for the Korean market with Encormac Corp....